Findings

What do systematic reviews say?

94 questions · 96 findings · 27 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 6.3%GRADE not reported 6 · 6.3%Very low 11 · 11.5%Low 31 · 32.3%Moderate 32 · 33.3%High 10 · 10.4%

Anti‐IL13 or anti‐IL4 agents vs placebo

Change from baseline in ACQ score Scale: 0 to 6 (higher is worse) · people with asthma

1 finding from 1 review

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 6251 participants
Moderate

Breathing exercises vs inactive control

Change in AQLQ · adults with asthma

1 finding from 1 review

Breathing exercises for adults with asthma 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 974 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Physical functioning component of health‐related quality of life, measured using various scales · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 267 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Quality of life Kansas City Cardiomyopathy Quality‐of‐Life questionnaire (higher scores indicate better quality of life) · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

QoL · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 163 participants
GRADE not reported

Selexipag vs placebo

mPAP (the higher the mPAP, the worse the pulmonary hypertension) · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Selexipag vs placebo

PVR · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Prostacyclin vs control

mPAP (the higher the mPAP, the worse the pulmonary hypertension) · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1132 participants
Low

Prostacyclin vs control

PVR · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 658 participants
Moderate

NMES and exercise vs exercise (with or without sham NMES)

Thigh muscle size · COPD

The review found no eligible studies for this question.

1 finding from 1 review

Neuromuscular electrostimulation for adults with chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

NMES vs usual care with or without sham interventions

Thigh muscle size · COPD

1 finding from 1 review

Neuromuscular electrostimulation for adults with chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 124 participants
Low

Summary of findings for AMBMT + PR vs PR

Dyspnoea ‐ CRQ dyspnoea Scale 1 to 7. Higher is better and 0.5 units is a clinically important difference · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Summary of findings for AMBMT vs PR

Change in dyspnoea score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Very low

Summary of findings for AMBMT + PR vs PR

General health‐related quality of life · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Summary of findings for AMBMT + PR vs PR

Health‐related quality of life (mental) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LABA/ICS (moderate certainty).

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
OR 0.87 [0.76, 1]
1 study · 3372 participants
Moderate

LABA/LAMA vs LAMA

Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in pneumonia: high‐risk population compared with LAMA (moderate certainty).

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
OR 0.98 [0.59, 1.61]
2 studies · 2510 participants
Moderate

LABA/LAMA vs LABA

Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

LABA/LAMA vs LABA

Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

LABA/LAMA vs LABA

Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported